TICKERNOMICS Sign up
Last Update: 2024-12-27 15:29:01
ALTERITY THERAPEUTICS LTD ( ATHE ) https://alteritytherapeutics.com
3.15USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
Australia
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
ATHE
27.49%
SPY
32.66%
-59.63%
ATHE
SPY
108.59%
-62.51%
ATHE
SPY
302.52%
-97.00%
ATHE
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
11490.31
11481.88
0.12
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-601.93
2802.17
1248.62
-0.10
0.00
-355.67
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-712.83
96.53
-699.38
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
6.344
-70.31
-70.53
0.55
Other Earnings and Cash Flow Stats:
ALTERITY THERAPEUTICS LTD ( ATHE ) Net Income TTM ($MM) is -19.42
ALTERITY THERAPEUTICS LTD ( ATHE ) Operating Income TTM ($MM) is -23.71
ALTERITY THERAPEUTICS LTD ( ATHE ) Owners' Earnings Annual ($MM) is -7.68
ALTERITY THERAPEUTICS LTD ( ATHE ) Current Price to Owners' Earnings ratio is -1111.56
ALTERITY THERAPEUTICS LTD ( ATHE ) EBITDA TTM ($MM) is -23.56
ALTERITY THERAPEUTICS LTD ( ATHE ) EBITDA Margin is -699.38%
Capital Allocation:
ALTERITY THERAPEUTICS LTD ( ATHE ) has paid 0.00 dividends per share and bought back -1221.033647 million shares in the past 12 months
ALTERITY THERAPEUTICS LTD ( ATHE ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
ALTERITY THERAPEUTICS LTD ( ATHE ) Interest-bearing Debt ($MM) as of last quarter is 0
ALTERITY THERAPEUTICS LTD ( ATHE ) Annual Working Capital Investments ($MM) are 0
ALTERITY THERAPEUTICS LTD ( ATHE ) Book Value ($MM) as of last quarter is 9
ALTERITY THERAPEUTICS LTD ( ATHE ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
ALTERITY THERAPEUTICS LTD ( ATHE ) has 8 million in cash on hand as of last quarter
ALTERITY THERAPEUTICS LTD ( ATHE ) has 3 million of liabilities due within 12 months, and long term debt 0 as of last quarter
ALTERITY THERAPEUTICS LTD ( ATHE ) has 3648 common shares outstanding as of last quarter
ALTERITY THERAPEUTICS LTD ( ATHE ) has 0 million USD of preferred stock value
Academic Scores:
ALTERITY THERAPEUTICS LTD ( ATHE ) Altman Z-Score is 1882.49 as of last quarter
ALTERITY THERAPEUTICS LTD ( ATHE ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
ALTERITY THERAPEUTICS LTD ( ATHE ) largest shareholder is Twin Lakes Capital Management, LLC owning 5925 shares at 0.02 ($MM) value
(an insider) shares of ALTERITY THERAPEUTICS LTD ( ATHE ) for the amount of $ on
0.00% of ALTERITY THERAPEUTICS LTD ( ATHE ) is held by insiders, and 0.86% is held by institutions
ALTERITY THERAPEUTICS LTD ( ATHE ) went public on 2002-09-05
Other ALTERITY THERAPEUTICS LTD ( ATHE ) financial metrics:
FCF:-13.34
Unlevered Free Cash Flow:-12.95
EPS:-0.01
Operating Margin:-712.83
Gross Profit Margin:96.53
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-357.47
Beta:0.55
Buffet's Owners Earnings:-7.68
Price to Owner's Earnings:-1111.56
About ALTERITY THERAPEUTICS LTD ( ATHE ) :
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.